Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (NCT00310180)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hormone therapy together with more than one chemotherapy drug (combination chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the benefit of adding chemotherapy to hormone therapy for women with node-negative, estrogen-receptor positive breast cancer is small. New tests may provide information about which patients are more likely to benefit from chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Northeast Alabama Regional Medical Center — Anniston, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1222 Sites)
Showing the first 25 of 1222 sites.
- Northeast Alabama Regional Medical Center — Anniston, Alabama
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
- Providence Hospital — Mobile, Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
- Alaska Regional Hospital — Anchorage, Alaska
- Providence Alaska Medical Center — Anchorage, Alaska
- Fairbanks Memorial Hospital — Fairbanks, Alaska
- Banner Thunderbird Medical Center — Glendale, Arizona
- Banner Desert Medical Center — Mesa, Arizona
- Banner Baywood Medical Center — Mesa, Arizona
- Banner-University Medical Center Phoenix — Phoenix, Arizona
- Western Regional CCOP — Phoenix, Arizona
- Virginia G Piper Cancer Care-Del Camino — Scottsdale, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
- Sparks Regional Medical Center — Fort Smith, Arkansas
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
- NEA Baptist Memorial Hospital — Jonesboro, Arkansas
- Saint Bernards Regional Medical Center — Jonesboro, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Arroyo Grande Community — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Adenocarcinoma
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer — Anniston, Alabama
- Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer — Houston, Texas
- Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca — Edgewood, Kentucky
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer — Mobile, Alabama
- Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer — Jacksonville, Florida
Explore by condition: All Breast Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.